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ABSTRACT
Multiple myeloma (MM) is a cancer of plasma cells in
the bone marrow (BM) and represents the second most
common hematological malignancy in the world. The
MM tumor microenvironment (TME) within the BM niche
consists of a wide range of elements which play important
roles in supporting MM disease progression, survival,
proliferation, angiogenesis, as well as drug resistance.
Together, the TME fosters an immunosuppressive
environment in which immune recognition and response
are repressed. Macrophages are a central player in the
immune system with diverse functions, and it has been
long established that macrophages play a critical role
in both inducing direct and indirect immune responses
in cancer. Tumor-associated macrophages (TAMs) are a
major population of cells in the tumor site. Rather than
contributing to the immune response against tumor cells,
TAMs in many cancers are found to exhibit protumor
properties including supporting chemoresistance,
tumor proliferation and survival, angiogenesis,
immunosuppression, and metastasis. Targeting TAM
represents a novel strategy for cancer immunotherapy,
which has potential to indirectly stimulate cytotoxic T cell
activation and recruitment, and synergize with checkpoint
inhibitors and chemotherapies. In this review, we will
provide an updated and comprehensive overview into
the current knowledge on the roles of TAMs in MM, as
well as the therapeutic targets that are being explored as
macrophage-targeted immunotherapy, which may hold key
to future therapeutics against MM.

INTRODUCTION
The bone marrow (BM) microenvironment
plays a key role in the development and
progression of multiple myeloma (MM).
Tumor-
associated macrophages (TAMs)
within the BM niche have recently captured
the attention of researchers as a potential
therapeutic target, given the plasticity and
range of functionality inherent to this cell
type. Prior reviews focusing on TAMs in
MM have discussed mechanisms of action
for which they support MM progression, as
well as potential treatment options for other
forms of malignancies that take advantage of





,1

these macrophages.1–4 In this review, we will
provide updated and comprehensive insight
into the current knowledge on the roles of
TAMs, as well as the therapeutic targets that
are being explored as macrophage-targeted
immunotherapy for MM.
Multiple myeloma
MM is a cancer of plasma cells in the BM and
represents the second most common hematological malignancy in the world.5 In the past
decade, therapeutic breakthroughs such as
proteasome inhibitors (PIs), immunomodubased therapeulatory drugs, and antibody-
tics have substantially expanded the number
of treatment regimens available for patients
in all stages of MM.6 However, MM remains
to be incurable because almost all patients
eventually relapse and/or become refractory
to treatment, and relapsed/refractory MM
(RRMM) has a lowered median survival of
only 5–15 months.7
Development of MM is preceded by two
asymptomatic precursor stages—monoclonal
gammopathy of undetermined significance
(MGUS) and smoldering MM (SMM). The
transition between healthy cells, MGUS,
SMM, and MM, as well as the progression of
MM, are heavily influenced by the development of the BM niche.8
The MM tumor microenvironment (TME)
within the BM niche consists of a wide range
of elements such as hematopoietic stem cells,
progenitor cells, mesenchymal stromal cells,
endothelial cells, immune cells, osteoblasts,
osteoclasts, adipocytes, extracellular matrix
proteins, and growth factors.9 10 TME components have been shown to play important
roles in supporting MM disease on multiple
levels, including MM progression, survival,
proliferation, angiogenesis, as well as drug
resistance.8 11 12 Together, the TME fosters an
immunosuppressive environment in which

Sun J, et al. J Immunother Cancer 2022;10:e003975. doi:10.1136/jitc-2021-003975

1

J Immunother Cancer: first published as 10.1136/jitc-2021-003975 on 15 April 2022. Downloaded from http://jitc.bmj.com/ on May 2, 2022 at Washington University School of Medicine
Library &. Protected by copyright.

Open access

immune recognition and response are repressed.13–15
Therefore, the BM niche is home to promising therapeutic targets for MM, and targeted reprogramming
of protumor TME components may hold key to future
therapeutics for MM. This review focuses on the crosstalk
between macrophages and MM tumor cells, which have
been a particularly promising area of study for MM and
other malignancies.
Macrophage polarization and functions
Macrophages are a major component of the innate
immune system and can be found across tissue types.16
The origin of tissue macrophages vary; some residential
macrophages derive from embryonic yolk sac or fetal
liver, while the adult macrophage population are understood to derive from the monocyte precursor through
hematopoiesis.17 Mature macrophages in the human
body are identifiable by the CD68, CD163, CD16, CD312,
and CD115 markers.16 18
Macrophages are recognized for their wide variety of
functions19; they are especially well known for their ability
to phagocytose pathogens and apoptotic cells, but their
contribution to the immunity and homeostasis of the
body goes far beyond phagocytosis.20 Macrophages are
highly plastic, and can activate and polarize for a specific
role depending on environmental cues.21 It is widely
accepted that polarized macrophages can be classified on
a spectrum of M1 and M2 phenotypes.
The classically activated M1 macrophages, which are
stimulated by interferon-γ (IFNγ) or lipopolysaccharide,
are identifiable by their proinflammatory properties and
are involved in the phagocytic and immune response.22
M1 macrophages express inducible nitric oxide synthase
and reactive oxygen species, which are both proinflammatory and aid in the killing of pathogens.23 24 These activated macrophages release inflammatory cytokines such
as interleukin (IL)-1, IL-6, IL-8, IL-12, and tumor-necrosis
factor α (TNFα) that aid in the immune response.21 The
M1 proinflammatory macrophages are also known to be
professional antigen-presenting cells (APCs), where they
phagocytose and present fragments of antigen on its
surface major histocompatibility complex (MHC) class II,
bridging to the adaptive immune system for a more efficient recognition of pathogens.18
The alternatively activated M2 macrophages are stimulated by IL-4. They are anti-inflammatory and participate
in immunosuppression and wound healing. They secrete
vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β) which promote angiogenesis and fibroblast activation at the wound site.25 26
Unlike M1 macrophages, M2 macrophages have minimal
antigen-
presenting ability. Variations in M2 macrophages have been observed in vitro, suggesting that M2
macrophages can be subdivided into M2a, M2b, or M2c
subtypes, thoroughly reviewed elsewhere.27

influenced by the TME.1 Rather than contributing to the
immune response against tumor cells, TAMs are often
found to exhibit protumor properties including chemoresistance, tumor proliferation and survival, angiogenesis, immunosuppression, and metastasis.28 29
TAMs originate from circulating monocytes recruited
into the tumor site, attracted by cytokines released by the
tumor, including VEGF, colony stimulating factor (CSF)-1,
CXC motif chemokine ligand (CXCL)-12, and the CC
chemokines, particularly CC motif chemokine ligand
(CCL)-2.2 3 Common TAM biomarkers include surface
markers CD163 and CD206, expression of arginase, as
well as production of VEGF, IL-10, and matrix metalloproteinases (MMPs).30 Due to their striking similarity in
function and phenotype, TAMs are often paralleled with
M2-like macrophages.31 TAMs secrete immunosuppressive cytokines such as IL-10 and TGF-β, which combine to
reduce T cell functionality and contribute to the immunosuppressive TME.32

THE ROLE OF TAMS IN MM
TAMs are a significant component in the BM of MM
patients, constituting around 10% of the BM.33 The prevalence of TAMs in MM has resulted in heightened attention invested into understanding the interplay between
MM cells and TAMs in order to identify novel immunotherapy targets. In this section, we will comprehensively discuss the various ways that TAMs influence MM
pathophysiology, including proliferation and survival,
angiogenesis, immunosuppression, and drug resistance
(figure 1).

Tumor-associated macrophages
TAMs are an important population of macrophages that
reside in the tumor site in large numbers and are heavily

MM proliferation and survival
The MM TAMs in the BM microenvironment have
been reported to heavily support MM proliferation and
survival. Increased infiltration of macrophages to the
tumor site is characteristic in MM patients compared with
healthy subjects, and that heightened number of CD163
or CD206 TAMs is a negative prognosis marker in MM
patients.34 35 Additionally, in a recent effort to identify the
immune landscape in various stages of MM, it was shown
that TAMs numbers dramatically increase in patients with
an aggressive form of MM.36 It was also revealed that TAMs
were among the most correlative informational marker
for therapeutic response in patients who underwent
standard-
of-
care chemotherapy treatment; patients not
achieving complete remission had higher frequencies of
TAMs, and the response to treatment positively correlated
with the number of TAMs at time of diagnosis.36
Additionally, soluble CD163 in patient serum was associated with poor survival outcomes; the BM microenvironment had localized production of soluble CD163, further
indicating the importance of macrophages in supporting
MM proliferation and survival outcomes.37
Mode of action behind TAM-
supported MM growth
has also been extensively explored under controllable
conditions using murine and cell line models. Multiple
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Figure 1 Tumor-associated macrophages (TAMs) play critical roles in multiple myeloma (MM) disease progression. This
figure highlights the known effects that TAMs exert on MM cells and cells within the MM tumor microenvironment, through
both secretion of molecules and contact-based surface interactions, which support proliferation and survival, angiogenesis,
immunosuppression, and drug resistance in MM. APC, antigen presenting cell; BAFF, B-cell activating factor; BTZ, bortezomib;
ICAM-1, intercellular adhesion molecule 1; IDO, indoleamine 2,3-dioxygenase; IFN-γ, interferon-γ; IL, interleukin; JAK/STAT3,
Janus kinase/signal transducer and activator of transcription proteins; MEL, melphalan; MHCII, major histocompatibility
complex class II; PSGL-1, P-selectin glycoprotein ligand-1; SIRPα, signal-regulatory protein α; VEGF, vascular endothelial
growth factor.

mechanisms have been revealed regarding TAM
supported MM proliferation, especially through prolific
secretion and regulation of various cytokines. Most
notably, TAMs have heightened IL-6 and IL-10 secretions,
and inhibited IL-12 and TNF-α secretions.38
IL-6 is a key cytokine that has pleiotropic functions
in both inflammation and immunity. In the context of
cancer, IL-6 has been shown to be critical for providing
survival benefits to variety of tumor types.39 In MM
patients, elevated IL-6 level correlates with adverse prognosis.40 Additionally, IL-6-deficient mice were completely
resistance to disease development, showing the essential
role of IL-6 in myeloma growth and survival.41 Ex vivo
interrogation revealed myeloid cells being the major IL-6
secreting cell type in the TME42; in vitro data demonstrated
that TAMs support MM cell survival through activation of
the IL-6/JAK/STAT3 pathway.43 Coculture of TAMs with

5T33MM murine MM cells provided survival benefits for
the myeloma cells, mediated through activation of STAT3
pathway in 5T33MM cells.44 STAT3 has also been shown
to be phosphorylated at a higher level in CD11b+cells of
MM-bearing mice compared with naïve mice.45 Thus, the
interplay of JAK/STAT activation in both MM and TAMs
relates to MM survival and pathogenesis.
Furthermore, it has been reported that IL-6 leads to the
production of IL-10, which also plays an important role in
the survival and proliferation of MM.38 46 In MM patients,
high IL-10 serum level correlates with disease prognosis,47
suggesting IL-10’s clinical significance in MM pathogenesis and progression.
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Angiogenesis
Proximity to vasculature is necessary for proliferation
and survival of MM by providing oxygen and nutrients.
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BM neovascularization in MM supports disease progression, and more evidence has been recovered to suggest
that TAMs in the BM microenvironment play a role
through angiogenic and vasculogenic activities.48
CD206 +Tie2+macrophages are found to correlate with
increased proangiogenic cytokines and microvessel
density in an MM mice model.49 IL-10 secreted by MM-associated TAMs positively correlates with angiogenic cytokines and proliferation markers.50
The main player in angiogenesis is VEGF. On its own,
MM can direct angiogenesis through its expression of
VEGF and secretion of the corresponding protein.51 On
the other hand, macrophages can also express and secrete
angiogenic factors, such as VEGF, CCLs, and MMPs.29
It was reported that TAMs and MM cells could synergistically promote human umbilical vein endothelial cells
(HUVECs) proliferation, migration, and tube formation
in vitro, and that VEGFA released from both cell types was
crucial to HUVEC tube formation ability.52 Additionally,
MM-associated macrophages exposed to VEGF and basic
fibroblast growth factor began to mimic vasculature by
acquiring endothelial cell markers and forming capillary-
like vessels.53 Thus, macrophages aid in angiogenesis in
MM through both direct and indirect means.

inhibits immunogenic response through inhibition of
CD4+ T cell growth, IL-2, IFNγ, and TNFα production.58
Finally, macrophages play a direct part in immune
evasion via the macrophage immune checkpoint CD47-
SIRPα. It has been shown that many solid and hematological malignancies overexpress the CD47 protein on the
surface as a protective ‘self-marker’.59 Binding of CD47 to
signal-regulatory protein alpha (SIRPα) receptor on the
surface of macrophages leads to downstream signaling
within the macrophages, resulting in inhibition of phagocytosis activity, thus the CD47-SIRPα interaction is also
known as the ‘don’t-eat-
me’ signal.60 In MM, CD47 is
overexpressed in CD138+ primary tumor cells compared
with normal BM cells, and positively correlates with the
stage of the disease,61–63 which lead to impaired immune
recognition.
In summary, MM-
associated macrophages secrete
signaling molecules that consequently suppress T cell
functions, in addition to actively participate in the CD47-
SIRPα checkpoint.

Immunosuppression
In addition to promoting tumor progression and angiogenesis, TAMs are also known to directly influence the
development of an immunosuppressive TME in many
cancer types. As a member of the innate immune system,
macrophages are essential in coordinating with the
adaptive immune system. Evidence has been reported
that TAMs participate in modifying immune cells to
increase presence of immunosuppressive cell types while
decreasing antitumor cell types.54 In MM, a few mechanisms have been reported, mainly pertaining to suppression of effector T cell activity.
MM-
primed macrophages decreased T cell proliferation and activation, through downregulation of IFN-γ
secretion.55 In a recent effort investigating BM immune
landscape changes in MM disease stages compared
with healthy donors using single-cell RNA sequencing,
it was revealed that dysregulation of MHC class II in
CD14 +monocytes conferred T cell suppression.56
IL-
10 is a key immunosuppressive cytokine mainly
secreted by myeloma-associated macrophages that participates in an array of tumor supportive activities, such as
tumor growth, angiogenesis, and disease progression.50 57
IL-10 is known to inhibit expression of MHC class II and
production of proinflammatory cytokines in APCs, which
in turn limit effector T cell functions.32
Indoleamine 2,3-
dioxygenase (IDO) is an enzyme
that degrades the essential amino acid tryptophan into
kynurenine. IDO is known to inhibit effector T cells and
promote differentiation of T regulatory cells (Tregs), thus
inhibiting the immune response. In MM, MM secreted
IL-32 increases production of IDO in macrophages, which

MM drug resistance
One of the greatest difficulties with MM from a clinical
standpoint is its tendency to develop resistance to treatment and relapse. In a clinical study, high TAM frequencies
in the patient MM BM was found to negatively correlate
with patient survival outcome with dexamethasone-
containing chemotherapy.64 An increasing amount of
research has been dedicated to seeking resistance mechanisms toward anti-MM drugs with contributions from MM
TAMs.
Macrophages enable drug resistance in MM through
both signaling and molecular contact based mechanisms.
One mechanism for resilience toward bortezomib is
through TAM secreted IL-1β, which resulted in increased
number of MM-tumor-initiating cells. It was found that
there was also an increase in the total number of proinflammatory macrophages (CD68+/CCR2+ in human and
F4/80+/CD11c+ in mice) within the BM following bortezomib exposure.65 Another mechanism for bortezomib
resistance was identified to be expression of B-cell activating factor (BAFF) by MM-
influenced macrophages.
BAFF was shown to activate MM survival through classical
and alternative NF-κB pathways, which prevented bortezomib induced apoptosis.66
Additionally, contact-based mechanisms have also been
reported. Myeloma/macrophage interaction pairs, P-selectin glycoprotein ligand-1(PSGL-1)/P-selectin and
ICAM-1/CD18, were reported to mediate resistance to
melphalan.67
Furthermore, macrophages also appear to respond
to factors from the TME to help MM resist drug treatment. For instance, the CCL2 chemokine not only
recruits macrophages and triggers their polarization to
the M2 phenotype, but also stimulates macrophages to
express the monocyte chemoattractant protein (MCP)-1-
induced protein (MCPIP1), which improves protection
of myeloma from bortezomib-induced apoptosis.68
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IMMUNOTHERAPEUTIC STRATEGIES TARGETING TAMS IN MM
Cancer immunotherapies targeting immune cells or the
interplay of immune and cancer cells have taken center
stage in oncology research. T cell-targeted immunotherapies have transformed the treatment landscape for many
cancers; however, these therapies are often limited by
variable patient responses.
As more evidence uncovers the crucial role of macrophages in MM pathogenesis, efforts have been made
to target MM-associated macrophages as a therapeutic
approach to MM. A great number of strategies have
been explored to target TAMs in a variety of cancers to
overcome immunosuppressive barriers.69 70 Increasing
numbers of preclinical studies are directed at blocking
protumor functions of TAMs and/or promoting their
antitumor activities.71 72
In this section, we will discuss different strategies used to
counteract macrophages’ supportive role in progression
of MM, including reducing TAMs, reprogramming TAMs,
inhibiting CD47/SIRPα checkpoint, overcoming immunosuppression, and reversing drug resistance (figure 2).
Reducing TAMs
Reducing the number of macrophages by direct killing is
one strategy to reduce macrophage tumor support. Direct
depletion of BM resident macrophages by clodronate-
liposome administration before cancer cell inoculation
resulted in impaired MM cell homing and tumor development.73 Moreover, a single dose of the clodronate-
liposome led to a significant reduction of tumor burden
in a C57BL/KaLwRijHsd murine model, suggesting
that direct depletion of BM macrophages is a promising
strategy for treatment of MM.
In contrast to direct killing of TAMs, controlling monocyte recruitment to the tumor and therefore reducing
TAM replenishment is more extensively explored. The
recruitment of monocytes/macrophages into tumors
is primarily regulated by cytokines, chemokines, and
growth factors that are derived from tumor and stromal
cells in the TME.
CXCL12-CXCR4 signaling is an important macrophage
recruitment mechanism to the MM BM.74 Research
has shown that MM cells highly express the chemokine
CXCL12; the CXCR4/CXCL12 axis not only contributes to MM cell adhesion and migration,75 but also
promotes monocyte recruitment and differentiation
toward a proangiogenic and immunosuppressive M2-like
phenotype with heightened CD206 expression and IL-10
production.55 Inhibition of CXCR4 with a neutralizing
antibody significantly suppressed monocyte recruitment
to the BM.55
The CC chemokines are demonstrated to be crucial
for macrophage infiltration in various types of cancers.76
CCL2, also well known as MCP-1, is a major player in
driving chemotaxis of myeloid and lymphoid cells. It
also maintains a scope of functions in various diseases
beyond migration, making it an attractive therapeutic
target.77 In MM, evidence shows that CCL2 is responsible
Sun J, et al. J Immunother Cancer 2022;10:e003975. doi:10.1136/jitc-2021-003975

Figure 2 Targeting TAMs as promising immunotherapy
for MM. Currently reported preclinical strategies
include (A) reducing TAMs, (B) reprogramming TAMs,
(C) inhibiting CD47/SIRPα checkpoint, (D) overcoming
immunosuppression, and (E) reversing drug resistance.
CCL2, CC motif chemokine ligand 2; CCR2, CC motif
chemokine receptor 2; CXCL12, CXC motif chemokine
ligand 12; CXCR4, CXC chemokine receptor type 4; CSF1R,
colony-stimulating factor-1 receptor; GM-CSF, granulocyte-
macrophage colony-stimulating factor; mAb, monoclonal
antibody; MIF, macrophage migration inhibitory factor; MM,
multiple myeloma; TAMs, tumor-associated macrophages.

for macrophage homing to the BM, as well as proliferation and polarization.78 Recently, it was demonstrated
that MM-secreted CCL2 in the microenvironment elicits
immunosuppressive MCP-
1-
induced protein (MCPIP1)
expression in macrophages via the JAK2-STAT3 pathway,
which promotes polarization toward the M2-
like
phenotype and protects MM cells from chemotherapy-
induced apoptosis. Inhibition of CCR2 receptor using
5
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a monoclonal antibody (mAb) disrupted this protective
effect.68 Targeting the CCR2/CCL2 axis has shown significant promise, preclinically and clinically, for blocking
TAM recruitment in many cancer types including liver,
pancreatic, and bladder cancers.79–81 Therefore, agents
such as an anti-CCL2 mAb or CCR2 antagonist could be
promising for disrupting macrophage recruitment in
MM.
Reprogramming TAMs
Rather than depletion of TAMs, more targeted therapies
are directed at blocking the protumor functions of TAMs,
while promoting antitumor activities. Reprogramming
TAMs to reduce their immunosuppressive M2 phenotype
and promote their immunostimulatory M1 phenotype,
represents a popular new field in MM treatment.
Gutiérrez-González et al reported a double treatment
strategy in which they introduced the pro-M1 cytokine
granulocyte–macrophage CSF (GM-
CSF) while simultaneously blocking the pro-
M2 cytokine macrophage
migration inhibitory factor with an inhibitor.82 This dual
treatment induced macrophage M1 genes and remarkable antitumor effects in vitro, performing better than
GM-
CSF treatment alone. Furthermore, this combination treatment resulted in macrophage-dependent therapeutic responses in a subcutaneous human MM cell line
xenograft mouse model, in which TAMs isolated from
treated mice had upregulated M1 and downregulated M2
markers compared with control animals. These results
prove that fine tuning of TAMs polarization toward antitumor phenotype is a promising strategy for treatment of
MM.82
In another report, Wang et al studied the potential
of treating MM by targeting macrophages using CSF
1 receptor (CSF1R)-
blocking mAbs.83 In vivo, CSF1R
blockade was able to inhibit MM growth by partially
depleting MM-
associated macrophages and polarizing
them to the M1 phenotype, as well as inducing a tumor-
specific CD4 +T cell response. Moreover, the combination of CSF1R blockade and bortezomib or melphalan
chemotherapy displayed additive therapeutic efficacy.
These results suggest that targeting macrophages with
anti-CSF1R mAbs may be a promising method to repolarize them to promote anti-
myeloma immune and
chemotherapy responses in MM patients.
Additionally, a JAK1/2 inhibitor Ruxolitinib has shown
promise in suppressing the M2 phenotype in macrophages through reducing Tribbles homolog 1 protein
kinase expression. In this preclinical study, treatment
with ruoxolitinib resulted in decreased M2 and increased
M1 polarization, both in vitro and in vivo, and was shown
to overcome resistance to lenalidomide.84
Targeting CD40 is another popular strategy to activate
macrophages in cancer. CD40 is a cell surface costimulatory protein found on APCs and is essential for their
activation.85 Agonistic CD40 antibodies is a promising
treatment of cancer patients through stimulating strong
activation of innate and adaptive immunity, which are
6

under clinical investigation in the solid tumor space.86
In myeloma, a preclinical study reported a macrophage
repolarizing effect using sequential CD40 activation and
TLR ligation. The immunotherapy with an agonistic anti-
CD40 antibody in combination with TLR agonist CpG
successfully elicited innate immune response toward MM
ex vivo and in vivo.87
Lastly, targeting the underlying mechanism by which
MM influence the development of TAMs represent a
novel therapy. Several recent studies focused on elucidating the MM-derived elements which mediate protumor
functions of MM-
associated macrophages. Zhang et al
showed that BMI1 protein to be a critical regulator in
macrophages under MM influence.88 Sonic hedgehog
secretion by myeloma was identified to be critical for
BMI1 upregulation though the Hedgehog-
Myc axis,
and inhibitors for Hedgehog signaling attenuated BMI1
expression in macrophages. BMI1 was further demonstrated to promote macrophage proliferation and confer
various promyeloma functions including angiogenesis,
chemoresistance, and myeloma growth. Finally, in a 5T
murine myeloma model, a BMI1 inhibitor PTC596 was
able to decrease tumor burden and prolong mice survival
through depletion of MM-macrophages.
We recently reported on the critical role of the IL-10/
IL-10R pathway in MM-TAM interaction. IL-10 secretion
from MM cells polarized macrophages toward heightened
M2 phenotype, and these macrophages in turn supported
MM proliferation and drug resistance. Inhibition of
IL-10/IL-10R signaling between the two cell types using
an IL-10R blocking antibody robustly reprogramed TAMs
to lose their M2 phenotype, in vitro, in vivo, and ex vivo.
Moreover, this resulted in the reversal of TAM supported
MM proliferation and overcame drug resistance toward
lenalidomide and dexamethasone.89
Inhibiting CD47/SIRPα checkpoint
Recently, immune checkpoints have been receiving
heightened attention in the field of cancer therapy.
Immune checkpoints are inhibitory mechanisms that
cancer cells use to escape from recognition and killing by
immune cells, effectively putting ‘breaks’ on the immune
system.90 While T cell immune checkpoint therapies
targeting PD-1/PD-L1 and CTLA-4 have shown progress
in various cancers, it has not been effective in treating
MM.91 Hence, targeting immune checkpoints in other
immune cells such as macrophages has been a topic of
discussion.
We and others have explored targeting CD47 using
anti-
CD47 mAbs to reverse immune suppression and
enhance macrophage mediated phagocytosis and killing
in MM.63 92 93 A plethora of CD47 targeting agents are
under clinical investigations, including anti-CD47 mAbs
and SIRPα fusion proteins.94
TTI-
621 is a SIRPα-IgG1 Fc fusion protein being
investigated in hematological malignancies in a phase
1b clinical trial (NCT02663518). In a preclinical study,
TTI-
621 effectively triggered macrophage-
mediated
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phagocytosis of MM cells. In an MM xenograft model,
it showed antitumor effects and further improved
efficacy when combined with PI drugs bortezomib or
carfilzomib.95
Similarly, the TTI-622 SIRPα-IgG4 Fc fusion protein is
also under clinical investigation in phase 1a/1b study for
advanced relapsed or refractory lymphoma or myeloma
(NCT03530683). In MM, TTI-
622 is being investigated as monotherapy and as combination therapy with
carfilzomib and dexamethasone. Preliminary data in
lymphoma patients show the agent is well-tolerated and
has dose-dependent binding, leading to cases of durable
responses.96
AO-
176 is a humanized IgG2 anti-
CD47 mAb that
showed preclinical anti-
MM activity in MM xenograft
models,93 and the efficacy was further demonstrated to
have combination effect with other anti-MM therapies
including bortezomib, daratumumab, lenalidomide,
or pomalidomide. Currently, a phase 1/2 clinical study
is underway to evaluate AO-176 as monotherapy and as
combination with bortezomib/dexamethasone in MM
patients (NCT04445701).
Another phase 1a/1b clinical trial is underway to study
SRF231, a fully human anti-CD47 mAb, as a monotherapy
in patients with advanced solid and hematological malignancies (NCT03512340).
based method in
Additionally, a novel microRNA-
155,
controlling CD47 has been reported using miR-
155 overexpression
a direct regulator of CD47. MiR-
suppressed CD47 expression on myeloma cells and
induced macrophage phagocytosis, which also reversed
bortezomib drug resistance in cell lines.97
In summary, inhibition of the CD47-
SIRPα axis
represents a promising strategy in boosting macrophage
immune surveillance activity, providing a great tool to
combat the immunosuppressive environment of the MM
BM niche.
Overcoming immunosuppression
Recently, preclinical strategies have been explored to
relieve the immunosuppressive environment through
targeting macrophage-related molecules. It was reported
that MM cells mediate the production of immunosuppressive IDO in macrophages, specifically through binding to
proteinase 3 (PR3) found on macrophages and activation of STAT3 and NF-κB pathways.58 Knockdown of PR3
or inhibition of STAT3 and NF-κB pathways in macrophages all reduced the capacity for IDO production in
vitro. Moreover, inhibition of IDO restored CD4 +T cell
proliferation and anti-inflammatory cytokine production.
Hence targeting pro-IDO mediators such as PR3 may be
a novel treatment to overcome macrophage mediated
immunosuppression. Another study directly targeted
IDO with a chemical inhibitor D,L-1-methyl-tryptophan
in patient primary cells, which reverted Tregs expansion and T helper type 1 inhibition that were resulted by
IDO.98
Sun J, et al. J Immunother Cancer 2022;10:e003975. doi:10.1136/jitc-2021-003975

Reversing drug resistance
Much evidence has been published to indicate that macrophages contribute to myeloma cell survival and resistance
to chemotherapeutic drugs such as melphalan and bortezomib. In addition to previously described TAM reprogramming methods to overcome M2 TAM supported
drug resistance, a few strategies have been explored to
target the crosstalk between TAMs and MM to overcome
drug resistance.
ICAM-1 on MM directly interacts with CD18 macrophages and is important for conferring drug resistance
to MM cells.67 99 100 As a result, ICAM-1 has been explored
as a candidate for immunotherapy in MM. BI-505 is a
mAb developed against ICAM-1 to enhance macrophage
activation.101 In preclinical studies, BI-505 decreased cell
growth and bone damage in the SCID-hu model. The in
vivo efficacy of BI-505 was macrophage dependent with
pronounced recruitment of monocyte/macrophages to
the diseased BM.101 In a phase 1 dose-escalation study
(NCT01025206), BI-505 was overall tolerable in RRMM
patients.102 However, to date, BI-505 has shown limited
clinical efficacy. Phase 2 clinical trials (NCT01838369) in
patients with SMM showed no clinical relevant response,103
and another phase 2 trial evaluating BI-505 in conjunction with autologous stem cell transplantation (ACST)
was put on hold by the U.S. Food and Drug Administration due to cardiovascular events (NCT02756728).
The STAT3 pathway is activated within MM cells when
cocultured with IL-
6 producing M2-
polarized macrophages. This leads to protection of MM cells from
apoptosis resulted by decreased cleavage of caspase-3.44
AZD1480, a potent and competitive small‐molecule
inhibitor of JAK1/2 kinases, was used as a strategy to
break this survival benefit. AZD1480 treatment in vitro
was effective on both MM cell and myeloid cell populations, and abrogated the TAM-mediated MM cell survival
by partially inhibiting resistance to bortezomib. Significant reduction of tumor load was observed with AZD1480
and bortezomib combination treatment in the murine
5T33MM model, and no significant killing of TAM populations were seen in vivo.44
To overcome macrophage-supported bortezomib resistance in myeloma, BAFF targeting by neutralizing antibody was investigated compared with bortezomib alone
in a subcutaneous xenograft model. Anti-BAFF antibody
in combination with bortezomib resulted in significantly
delayed tumor growth compared with bortezomib alone,
indicating BAFF as a favorable target for reversing bortezomib resistance in MM.66
FUTURE DIRECTIONS AND CONCLUSIONS
In recent years, immunotherapy has taken center stage
in the field of cancer treatment. Modulation of the
immune system to induce a durable response represents
an exciting idea with potential to elicit superior efficacy
than traditional therapies. Much of the current attention
focuses on the engagement of T cells, with PD-1/PD-L1
7
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Table 1 Clinical investigation of immunotherapeutic strategies targeting TAMs in MM
Strategy

Agent

Reducing TAMs
Reprogramming TAMs

None
None

Inhibiting CD47-SIRPα
Checkpoint

Overcoming
Immunosuppression
Reversing drug resistance

Description

Clinical trial ID

Phase

Status

TTI-621

SIRPα-IgG1 Fc fusion protein

NCT02663518

Phase Ib

Recruiting

TTI-622

SIRPα-IgG4 Fc fusion protein

NCT03530683

Phase Ia/Ib

Recruiting

AO-176

Humanized IgG2 anti-CD47 mAb

NCT04445701

Phase I/II

Recruiting

SRF231

Fully human anti-CD47 mAb

NCT03512340

Phase Ia/Ib

Completed

BI-505

Fully human anti-ICAM-1 mAb

NCT01025206

Phase I

Completed

BI-505
None

Fully human anti-ICAM-1 mAb

NCT02756728

Phase I/II

Terminated

mAb, monoclonal antibody; MM, multiple myeloma; SIRPα, signal regulatory protein α; TAMs, tumor-associated macrophages.

checkpoint inhibition being explored in over 3000 clinical trials.104 While there has been considerable success in
T cell-targeted therapies, variable response and low T cell
infiltration presents a road block.
Expanded investigation toward other immune players
poses a novel area of research. Macrophages are crucial
players of the innate immune system and present in
high numbers in the TME. Thus, heightened attention
is directed toward studying the role of macrophages in
cancer. Increased amount of evidence reports prevalence of TAMs in various malignancies, and their tumor-
supportive characteristics in promoting progression and
drug resistance. Therefore, unearthing novel insights
into mechanisms allowing TAMs’ tumor-promoting roles
will provide new clues for future macrophage-targeted
tumor therapy.
In this review, we provided an overview of the current
knowledge of TAMs’ contribution in MM, including their
role in proliferation, angiogenesis, immunosuppression,
and drug resistance. We also reviewed classes of preclinical strategies targeting TAMs for MM immunotherapy,
with many showing promising results. However, no clinical
trials are in progress for immunotherapy strategy aside
from those focusing on the CD47 checkpoint (table 1).
A number of key questions remain to be answered. For
example, most of what is known regarding the role of
macrophages in generating an immunosuppressive environment is about its effect on CD4 +effector T cells. In
the future, more studies are warranted to investigate its
effect on additional antitumor immune cell populations,
such as CD8 +cytotoxic T cells, B cells, and NK cells, as
well as other immunosuppressive populations such as
regulatory T cells.
ACST remains to be a critical standard of care for
younger myeloma patients. However, limited clinical
data is available regarding the role of macrophages in
efficacy of such therapy. In a clinical study investigating
TAM numbers and response to therapy in MM patients,
the response rate was not significantly different between
TAM and low-
TAM groups that received chemohigh-
therapy and ACST.35 In another study, a preclinical

murine model of ACST showed the CSF-1R expression
level on BM macrophages 6 weeks after ACST was significantly higher in animals that relapsed compared with
those that were progression-free.105 More investigation
is warranted for the correlation between macrophage
population, including accumulation and phenotype, to
the patient’s prognostic outcome.
In addition, cellular therapy is on the rise to take center
stage in immunotherapy. While no genetically engineered
macrophages have been reported in myeloma, such
methods are being explored in the realm of solid tumors
with considerable progress.106 107 In MM, one interesting
approach was reported to use myeloid cells as cellular
carriers of oncolytic for treatment of myeloma. The
myeloid cells successfully localized to tumors and transferred infection to myeloma cells, prolonging survival in
an MM xenograft model.108
Lastly, synergistic combination of TAM targeting strategies with popular T cell-targeted immunotherapies could
be promising, potentially inducing robust improvements
in the efficacy of checkpoint inhibition, T cell engagers,
as well as CAR-T therapies by removing TAM-mediated
immunosuppression.109
In conclusion, TAM-
targeting therapy represents a
promising treatment for cancer patients. This class of
therapy could supplement current T cell therapies,
impacting the current treatment regimen by overcoming
unresponsiveness and drug resistance. More research is
warranted to elucidate underlying molecular processes
between macrophages, MM cells, and subpopulations of
the TME, and strategies need to be verified in a clinical
setting.
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